Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis
| dc.creator | Tsivgoulis G., Katsanos A.H., Voumvourakis K., Hadjigeorgiou G.M., Heliopoulos I., Karapanayiotides T., Papathanasopoulos P., Kilidireas C., Grigoriadis N. | en |
| dc.date.accessioned | 2023-01-31T10:16:46Z | |
| dc.date.available | 2023-01-31T10:16:46Z | |
| dc.date.issued | 2018 | |
| dc.identifier | 10.1016/j.msard.2018.03.010 | |
| dc.identifier.issn | 22110348 | |
| dc.identifier.uri | http://hdl.handle.net/11615/80067 | |
| dc.description.abstract | [No abstract available] | en |
| dc.language.iso | en | en |
| dc.source | Multiple Sclerosis and Related Disorders | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85046745230&doi=10.1016%2fj.msard.2018.03.010&partnerID=40&md5=17a196c2f9f190eb3315dc6e4cf1d8ea | |
| dc.subject | alemtuzumab | en |
| dc.subject | beta1a interferon | en |
| dc.subject | glatiramer | en |
| dc.subject | natalizumab | en |
| dc.subject | ocrelizumab | en |
| dc.subject | glatiramer | en |
| dc.subject | clinical effectiveness | en |
| dc.subject | drug efficacy | en |
| dc.subject | human | en |
| dc.subject | immunotherapy | en |
| dc.subject | Letter | en |
| dc.subject | methodology | en |
| dc.subject | monotherapy | en |
| dc.subject | multiple sclerosis | en |
| dc.subject | randomized controlled trial (topic) | en |
| dc.subject | therapy effect | en |
| dc.subject | treatment outcome | en |
| dc.subject | multiple sclerosis | en |
| dc.subject | Glatiramer Acetate | en |
| dc.subject | Humans | en |
| dc.subject | Multiple Sclerosis | en |
| dc.subject | Multiple Sclerosis, Relapsing-Remitting | en |
| dc.subject | Elsevier B.V. | en |
| dc.title | Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis | en |
| dc.type | other | en |
Αρχεία σε αυτό το τεκμήριο
| Αρχεία | Μέγεθος | Τύπος | Προβολή |
|---|---|---|---|
|
Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο. |
|||

